What does the evidence say about Creatine Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Creatine Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Leg-press 1RM (k = 3; n = 111) improved with creatine: MD + 7.5 kg (95% CI + 2.2 to + 12.8; I² = 0%). [Naddafha S (2026); evidence level 1] - Risk of bias was mostly "some concerns;" one large, preregistered, double-blind RCT was at low risk. [Naddafha S (2026); evidence level 1] - Conclusions In postmenopausal women, creatine, particularly ≥ 5 g·day⁻¹ with RT, yields small but meaningful gains in lean mass and strength without evidence of harm. [Naddafha S (2026); evidence level 1] - Background Menopause is accompanied by accelerated losses in muscle mass and strength and declining bone density. [Naddafha S (2026); evidence level 1] - ABSTRACT NUMBER: ESOC2026OT29 EFFECT OF CREATINE MONOHYDRATE SUPPLEMENTATION ON RECOVERY AFTER ISCHEMIC STROKE: THE SUCRE CLINICAL TRIAL [ABSTRACT NUMBER: ESOC2026OT29 EFFECT OF CREATINE MONOHYDRATE SUPPLEMENTATION ON RECOVERY AFTER ISCHEMIC STROKE: THE SUCRE CLINICAL TRIAL (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.